Company: LCTX
Filing Date: 2025-03-10
Form Type: 10-K
Source: 0000950170-25-036309
Chunk: 119

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-03-10
Form: 10-K
Item: Item 1A
Chunk 119
---
 and the level of expenses related to development of our product candidates;

•announcements or expectations of additional financing efforts;

•sales of our common shares by us, our insiders or other shareholders;

•trading volume of our common shares;

•changes in the market valuation of companies perceived to be comparable to us;

70

•actual or anticipated variations in our operating results;

•changes in accounting policies and practices or material weakness or ineffectiveness of our internal controls or disclosure controls;

•disagreements with our auditor or termination of an auditor engagement;

•disputes or other developments relating to proprietary rights, including patents and trade secrets, or other avenues of market exclusivity for our product candidates or products and product candidates perceived to be competitive to ours;

•changes in the structure of healthcare payment systems;

•significant lawsuits, including intellectual property, product liability or shareholder litigation;

•publication of research reports about us or our industry, or cell therapies in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts;

•actual or potential suspension of trading or delisting of our common shares by stock exchanges. 

•inclusion or exclusion of our common shares in or from stock indices such as the Russell 3000® Index;

•significant business disruptions caused by natural or man-made disasters, prolonged public health emergencies, wars and other armed conflicts, and regional instability, including in and around Ukraine and Israel;

•market conditions in the biotechnology sector and general political and economic conditions; and

•other factors described in this Risk Factors section.

In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of their shares. This type of litigation, if instituted against us, could result in substantial costs and a diversion of our management’s attention and resources, which could materially and adversely affect our business and financial condition.

Because we do not intend to pay cash dividends, our common shares may not be a suitable investment for anyone who needs to earn dividend income. 

We do not pay cash dividends on our common shares. For the foreseeable future, we anticipate that any earnings generated in our business will be used to finance the growth of our business and will not be paid out as dividends to holders of our common shares. This means that any return to our shareholders will be limited to the appreciation of their shares and, therefore, our common shares may not be a suitable investment for anyone who needs to earn dividend income from their investments.

Insiders continue to have substantial influence over our company, which could limit your ability